Intraoperative Magnesium Sulfate Administration During Orthotopic Liver Transplantation

Sponsor
Fayoum University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT03717467
Collaborator
(none)
60
1
2
25.8
2.3

Study Details

Study Description

Brief Summary

The aim of study is to assess the effect of intraoperative use of magnesium sulfate in liver donating patients in reducing post-operative morphine requirements in early postoperative 24 hour in adult living liver donor.The authors hypothesize that magnesium sulfate can be used to efficiently reduce postoperative morphine consumption in the early 24 hours postoperatively as evident in other surgery types.

Condition or Disease Intervention/Treatment Phase
  • Drug: isotonic saline
  • Drug: Magnesium Sulfate
N/A

Detailed Description

Introduction A lot of recent trials emphasized that perioperative magnesium sulfate (MgSO4) infusion has general anesthetic properties that could reduce anesthetic drug consumption and postoperative analgesia requirements in several types of surgery. Optimal post-operative pain control is necessary for early mobilization, improved respiratory function, and deep venous thrombosis. Administration of multimodal analgesics could limit the excessive use of systemic opioid analgesia especially (morphine), which has a high rate of postoperative side effects as sedation, respiratory depression, ileus, nausea, vomiting, constipation, urine retention, and itching. Therefore, medications and adjuvant drugs reducing the need for opioids have become widely used as parts of multimodal analgesia. Post-operative pain management begins with pre-operative planning and formulating a pain management plan that is tailored to an individual patient's liver function, respiratory and coagulation status, comorbidities and extent of resection.

Anesthetic technique:

Patients will be premedicated with tablet of alprazolam 0.25 mg the night before and 2 hours before surgery. Upon arrival in operating room usual monitoring will be established including heart rate, blood pressure, electrocardiogram (ECG),and temperature. After induction of anesthesia, an arterial line will be inserted for continuous monitoring of blood pressure and frequent blood gas analysis. End-tidal carbon dioxide (capnography) will be attached. General anesthesia will be administered using propofol 2 mg/kg, morphine 0.1 mg/kg and atracurium besylate 0.5 mg/kg followed by oral endotracheal intubation. Maintenance of general anesthesia with a mixture of isoflurane and 50% oxygen in air, morphine 2 mg/ h, mechanical ventilation will be adjusted to keep arterial oxygen saturation < 95 % and end-tidal carbon dioxide between 35 and 40 mmHg. Atracurium (0.15 mg/kg) will be administered every 30 min.

Baseline intravenous infusion rate of lactated ringers solution will be set at (6ml/ kg/h) in both groups, additional solution will be infused if required. Magnesium sulfate infusion and anesthetic agents will be discontinued at the end of operation. The postoperative residual neuromuscular blockade will be reversed by using neostigmine 0.04 mg/kg and atropine 0.02 mg/kg. Then the patient will be extubated and transferred to the post-anesthesia care unit (PACU) for 1-hour observation.

Statistical analysis:

Statistical analysis will be done using Statistical Package for Social Sciences (SPSS) version 19 for Windows software. Data will be collected from all patients during and after anesthesia. Descriptive statistics (mean, standard deviation, or median and ranges) will be calculated. Comparative statistics between the two groups will be applied. Unpaired t-test will be used to compare the mean values between the two groups. The Kolmogorov-Smirnov test will be implemented to check the normality of continuous data distribution (P ≤ 0.05) Mann-Whitney-U test will be used to compare difference between the two groups for non-parametric variables (e.g.VAS). While the Chi-square test will be used to compare the categorical variables between both groups. The significant result will be considered when P value was less than (0.05).

Sample size calculations of this trial will be done upon the following assumption, α = 0.05 β = 0.2, effect size will be =0.7.The effect size is calculated by using G*Power software version 3.1.9.2 (Institute of Experimental Psychology, Heinrich Heine University, Dusseldorf, German) and the authors found that 25 patients in each group have a power of 80% and plan to recruit 30 patients per group to account for possible dropout.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Masking Description:
Patient will be randomly assigned to one of the two groups. An independent anesthesiologist who will not be participating in the study prepares the study medications.
Primary Purpose:
Prevention
Official Title:
The Influence of Intraoperative Magnesium Sulfate Administration on Postoperative Morphine Requirement in Living Donor During Orthotopic Liver Transplantation
Actual Study Start Date :
May 8, 2019
Anticipated Primary Completion Date :
Jun 1, 2021
Anticipated Study Completion Date :
Jul 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: S group

Isotonic saline as placebo will be given.

Drug: isotonic saline
100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
Other Names:
  • Saline group
  • Active Comparator: M group

    Magnesium sulfate will be given

    Drug: Magnesium Sulfate
    40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
    Other Names:
  • Magnesium group
  • Outcome Measures

    Primary Outcome Measures

    1. Postoperative Morphine consumption [24 hours after operation]

      in mg

    Secondary Outcome Measures

    1. Mean arterial pressure [1 minute before induction]

      in mm mercury by invasive blood pressure

    2. Heart rate [1 minute before induction]

      in beat per minute by electrocardiogram

    3. Mean arterial pressure [30 seconds before intubation]

      in mm mercury by invasive blood pressure

    4. Heart rate [30 seconds before intubation]

      in beat per minute by electrocardiogram

    5. Mean arterial pressure [5 minutes after beginning of surgery]

      in mm mercury by invasive blood pressure

    6. Heart rate [5 minutes after beginning of surgery]

      in beat per minute by electrocardiogram

    7. Mean arterial pressure [15 minutes after beginning of surgery]

      in mm mercury by invasive blood pressure

    8. Heart rate [15 minutes after beginning of surgery]

      in beat per minute by electrocardiogram

    9. Mean arterial pressure [30 minutes after beginning of surgery]

      in mm mercury by invasive blood pressure

    10. Heart rate [30 minutes after beginning of surgery]

      in beat per minute by electrocardiogram

    11. Mean arterial pressure [60 minutes after beginning of surgery]

      in mm mercury by invasive blood pressure

    12. Heart rate [60 minutes after beginning of surgery]

      in beat per minute by electrocardiogram

    13. Mean arterial pressure [120 minutes after beginning of surgery]

      in mm mercury by invasive blood pressure

    14. Heart rate [120 minutes after beginning of surgery]

      in beat per minute by electrocardiogram

    15. Mean arterial pressure [30 minutes after end of surgery]

      in mm mercury by invasive blood pressure

    16. Heart rate [30 minutes after end of surgery]

      in beat per minute by electrocardiogram

    17. Morphine consumption [30 minutes after end of surgery]

      in milligram

    18. Visual Analog Scale [30 minutes after end of surgery]

      Pain score which starting from 0:no pain to 10:Worst pain

    19. Assessment of sedation [30 minutes after end of surgery]

      By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake

    20. Mean arterial pressure [4 hours after end of surgery]

      in mm mercury by invasive blood pressure

    21. Heart rate [4 hours after end of surgery]

      in beat per minute by electrocardiogram

    22. Morphine consumption [4 hours after end of surgery]

      in milligram

    23. Visual Analog Scale [4 hours after end of surgery]

      Pain score which starting from 0:no pain to 10:Worst pain

    24. Assessment of sedation [4 hours after end of surgery]

      By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake

    25. Mean arterial pressure [24 hours after end of surgery]

      in mm mercury by invasive blood pressure

    26. Heart rate [24 hours after end of surgery]

      in beat per minute by electrocardiogram

    27. Morphine consumption [24 hours after end of surgery]

      in milligram

    28. Visual Analog Scale [24 hours after end of surgery]

      Pain score which starting from 0:no pain to 10:Worst pain

    29. Assessment of sedation [24 hours after end of surgery]

      By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake

    30. Mean arterial pressure [48 hours after end of surgery]

      in mm mercury by invasive blood pressure

    31. Heart rate [48 hours after end of surgery]

      in beat per minute by electrocardiogram

    32. Morphine consumption [48 hours after end of surgery]

      in milligram

    33. Visual Analog Scale [48 hours after end of surgery]

      Pain score which starting from 0:no pain to 10:Worst pain

    34. Assessment of sedation [48 hours after end of surgery]

      By 5-point sedation Ramsay score where 5:aroused only by shaking 4:difficult response to verbal 3:mostly sleeping but easily aroused 2:drowsy 1:awake

    35. Patient satisfaction level [48 hours after end of surgery]

      By 5-point scale where 1: very unsatisfactory 2:unsatisfactory 3:neutral 4:satisfactory 5:Excellent

    36. Blood serum magnesium concentration [12 hours before operation]

      from venous blood sample in mg/dl

    37. Blood serum magnesium concentration [15 minutes after operation]

      from venous blood sample in mg/dl

    38. Interleukin 6 level in blood [24 hours after operation]

      inflammatory mediator measured from venous blood sample

    39. Interleukin 8 level in blood [24 hours after operation]

      inflammatory mediator measured from venous blood sample

    40. Tumor necrosis factor alpha level in blood [24 hours after operation]

      inflammatory mediator measured from venous blood sample

    41. Incidence of shivering [48 hours after operation]

      as opioid related side effect

    42. Incidence of nausea [48 hours after operation]

      as opioid related side effect

    43. Incidence of vomiting [48 hours after operation]

      as opioid related side effect

    44. Incidence of respiratory depression [48 hours after operation]

      as opioid related side effect

    45. Incidence of somnolence [48 hours after operation]

      as opioid related side effect

    46. Incidence of oversedation [48 hours after operation]

      as opioid related side effect

    47. Incidence of itching [48 hours after operation]

      as opioid related side effect

    48. Incidence of constipation [48 hours after operation]

      as opioid related side effect

    49. Incidence of paralytic ileus [48 hours after operation]

      as opioid related side effect

    Other Outcome Measures

    1. Age [1 hour before operation once patient is recruited]

      in years

    2. Height [1 hour before operation once patient is recruited]

      in meters

    3. Weight [1 hour before operation once patient is recruited]

      in kilogram

    4. body mass index [1 hour before operation once patient is recruited]

      kilogram/meter square

    5. Surgery duration [1 minute after operation]

      in hours

    6. Anesthesia duration [1 minute after withdrawal of all anesthetics]

      in hours from time of induction to withdrawal of all anesthetics

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age (18-50).

    • American Society of Anesthesiology (ASA) physical state I or II.

    • Normal serum electrolytes.

    Exclusion Criteria:
    • Impaired hepatic or renal functions.

    • Various degree of heart block.

    • Hypertension

    • Diabetes

    • Myopathy or any neurological disorder.

    • History of long term opioid use

    • Patients treated with calcium channel blockers

    • Patients with known allergy to drug used.

    • Pregnant woman

    • Obesity (Body Mass Index > 30).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sheikh Zayed hospital Giza Egypt 12573

    Sponsors and Collaborators

    • Fayoum University Hospital

    Investigators

    • Study Chair: Mostafa S Elhamamsy, MD, Faculty of medicine, Fayoum University
    • Study Director: Ahmed M Yassin, MD, Faculty of medicine, Beni-suef University
    • Study Director: Abeer S Goda, MD, Faculty of medicine, Fayoum University
    • Principal Investigator: Hany M Yassin, MD, Faculty of medicine, Fayoum University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Hany M Yassin, MD, Associate professor of anesthesia, Fayoum University Hospital
    ClinicalTrials.gov Identifier:
    NCT03717467
    Other Study ID Numbers:
    • D129
    First Posted:
    Oct 24, 2018
    Last Update Posted:
    Nov 9, 2020
    Last Verified:
    Nov 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Hany M Yassin, MD, Associate professor of anesthesia, Fayoum University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 9, 2020